Biocon's Biosimilar Blues
The Morning Brief
00:00
Biocon's Transform National Deal Fails to Impress La Street Analysts
Biocon has lost nearly six thousand cror of its market cap since the announcement of the deal. The viatis stock has dropped 30 % during the same period. So why this transform national deal failed to impress the la street and spooked analyst as well? For that, i turned to vickars. It's important to understand how they will be funding this deal - it's like three point three billion dollar.
Play episode from 07:42
Transcript
